ArticleDiscover nano2026
Chitosan nanoparticle encapsulated pentoxifylline improves renal protection and reduces oxidative stress in amikacin induced nephrotoxicity.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amikacin (AMK)-induced nephrotoxicity remains a clinical challenge, necessitating innovative therapeutic strategies. This study developed pentoxifylline-loaded chitosan nanoparticles (PTX-CSNPs) to enhance PTX's renoprotective effects while minimizing its side effects. PTX-CSNPs were synthesized via ionic gelation, exhibiting high entrapment efficiency (89.53%) and sustained release (87% at 48 h). Characterization revealed spherical nanoparticles (30-50 nm by TEM and 79.05 nm by DLS) with positive zeta potential (+ 32.77 mV), confirmed by FTIR and XRD analyses. In vitro, PTX-CSNPs demonstrated superior antioxidant (98.73% DPPH scavenging), anti-inflammatory (76.46% RBCs membrane stabilization), and anticoagulant activity compared to free PTX. In vivo, AMK-induced nephrotoxic rats treated with PTX-CSNPs showed normalization of renal function biomarkers (BUN, creatinine, uric acid) and oxidative stress markers (MDA, SOD, GSH), alongside reduced inflammatory markers levels outperforming free PTX or CSNPs alone. Histopathology revealed preserved glomerular and tubular architecture. The nanoformulation's efficacy was attributed to chitosan-mediated targeted delivery and PTX's anti-inflammatory/antioxidant synergy. These findings highlighted PTX-CSNPs as a promising nanotherapeutic for drug-induced kidney injury, offering enhanced bioavailability and reduced systemic toxicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.